RecruitingPhase 3NCT07777822

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

Sponsor

Revolution Medicines, Inc.

Enrollment

430 participants

Start Date

Aug 14, 2026

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer NSCLC Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer Metastatic NSCLC - Non-Small Cell Lung Cancer Metastatic Non-Squamous Non-Small Cell Lung Cancer

Summary

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo, a drug called pembrolizumab, and others for people with lung cancer (nsclc), metastatic nsclc - non-small cell lung cancer, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGzoldonrasib

oral tablets

DRUGPlacebo

oral tablets

DRUGpembrolizumab

IV infusion or Subcutaneous injection

DRUGpemetrexed + cisplatin /carboplatin

IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin

Locations(1)

Florida Clinical Trials Group, LLC

Plantation, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07777822

Related Trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738312 locations

Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT07435038

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

NCT06767514270 locations

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT0526762618 locations

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

NCT0751337646 locations